JP2023540904A - タンパク質および核酸をアッセイするための組成物および方法 - Google Patents

タンパク質および核酸をアッセイするための組成物および方法 Download PDF

Info

Publication number
JP2023540904A
JP2023540904A JP2023513345A JP2023513345A JP2023540904A JP 2023540904 A JP2023540904 A JP 2023540904A JP 2023513345 A JP2023513345 A JP 2023513345A JP 2023513345 A JP2023513345 A JP 2023513345A JP 2023540904 A JP2023540904 A JP 2023540904A
Authority
JP
Japan
Prior art keywords
proteins
particles
biological sample
protein
nanoparticles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023513345A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023540904A5 (enExample
Inventor
ダニエル ホーンバーグ，
マイケル フィガ，
シャオヤン ジャオ，
アシム エス． シディキ，
フィリップ マ，
サンテ キム，
オミッド シー． ファロクザド，
マーガレット ドノヴァン，
ジョン イー． ブルーム，
セオドア プラット，
マーティン ゴールドバーグ，
ダミアン ハリス，
Original Assignee
シアー， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シアー， インコーポレイテッド filed Critical シアー， インコーポレイテッド
Publication of JP2023540904A publication Critical patent/JP2023540904A/ja
Publication of JP2023540904A5 publication Critical patent/JP2023540904A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/54326—Magnetic particles
    • G01N33/54333—Modification of conditions of immunological binding reaction, e.g. use of more than one type of particle, use of chemical agents to improve binding, choice of incubation time or application of magnetic field during binding reaction
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869—Methods for sequencing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N1/00—Sampling; Preparing specimens for investigation
    • G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
    • G01N1/40—Concentrating samples
    • G01N1/405—Concentrating samples by adsorption or absorption
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2531/00—Reactions of nucleic acids characterised by
    • C12Q2531/10—Reactions of nucleic acids characterised by the purpose being amplify/increase the copy number of target nucleic acid
    • C12Q2531/113—PCR
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2535/00—Reactions characterised by the assay type for determining the identity of a nucleotide base or a sequence of oligonucleotides
    • C12Q2535/122—Massive parallel sequencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2537/00—Reactions characterised by the reaction format or use of a specific feature
    • C12Q2537/10—Reactions characterised by the reaction format or use of a specific feature the purpose or use of
    • C12Q2537/159—Reduction of complexity, e.g. amplification of subsets, removing duplicated genomic regions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2570/00—Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7023—(Hyper)proliferation
    • G01N2800/7028—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Peptides Or Proteins (AREA)
  • Nanotechnology (AREA)
JP2023513345A 2020-08-25 2021-08-24 タンパク質および核酸をアッセイするための組成物および方法 Pending JP2023540904A (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US202063070205P 2020-08-25 2020-08-25
US63/070,205 2020-08-25
US202063112071P 2020-11-10 2020-11-10
US63/112,071 2020-11-10
US202163143738P 2021-01-29 2021-01-29
US63/143,738 2021-01-29
US202163166173P 2021-03-25 2021-03-25
US63/166,173 2021-03-25
US202163194612P 2021-05-28 2021-05-28
US63/194,612 2021-05-28
PCT/US2021/047397 WO2022046804A2 (en) 2020-08-25 2021-08-24 Compositions and methods for assaying proteins and nucleic acids

Publications (2)

Publication Number Publication Date
JP2023540904A true JP2023540904A (ja) 2023-09-27
JP2023540904A5 JP2023540904A5 (enExample) 2024-09-03

Family

ID=80355675

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023513345A Pending JP2023540904A (ja) 2020-08-25 2021-08-24 タンパク質および核酸をアッセイするための組成物および方法

Country Status (10)

Country Link
US (2) US12276668B2 (enExample)
EP (1) EP4204580A4 (enExample)
JP (1) JP2023540904A (enExample)
KR (1) KR20230079044A (enExample)
CN (1) CN116529393A (enExample)
AU (1) AU2021333661A1 (enExample)
CA (1) CA3190719A1 (enExample)
DE (1) DE112021004478T5 (enExample)
IL (1) IL300826A (enExample)
WO (1) WO2022046804A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2595583A (en) 2018-11-07 2021-12-01 Seer Inc Compositions, methods and systems for protein corona analysis and uses thereof
CA3131402A1 (en) 2019-03-26 2020-10-01 Xiaoyan Zhao Compositions, methods and systems for protein corona analysis from biofluids and uses thereof
KR20240137114A (ko) 2019-08-05 2024-09-19 시어 인코퍼레이티드 샘플 제조, 데이터 생성, 및 단백질 코로나 분석을 위한 시스템 및 방법
WO2021087407A1 (en) * 2019-11-02 2021-05-06 Seer, Inc. Systems for protein corona analysis
JP2023540904A (ja) 2020-08-25 2023-09-27 シアー， インコーポレイテッド タンパク質および核酸をアッセイするための組成物および方法
CN114854859A (zh) * 2022-05-05 2022-08-05 四川省肿瘤医院 一种基于血小板内FlnA基因表达量的肺结节良恶性诊断方法
IL317700A (en) * 2022-06-15 2025-02-01 Seer Inc Systems and methods for testing biomolecules
WO2024011232A1 (en) * 2022-07-08 2024-01-11 Seer, Inc. Methods for analyzing biological samples
WO2025184649A1 (en) * 2024-03-01 2025-09-04 University Of South Florida Methods of inhibiting m6a reader ythdf1 for treating neurodegenerative disease

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020096631A2 (en) * 2018-11-07 2020-05-14 Seer, Inc. Compositions, methods and systems for protein corona analysis and uses thereof

Family Cites Families (138)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4863873A (en) 1980-01-14 1989-09-05 Esa, Inc. Method for biological testing and/or developing pharmaceuticals for treatment of disorders
US4444879A (en) 1981-01-29 1984-04-24 Science Research Center, Inc. Immunoassay with article having support film and immunological counterpart of analyte
CA1340966C (en) 1989-05-19 2000-04-18 Thomas R. Covey Method of protein analysis
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5366140A (en) 1993-09-30 1994-11-22 Minnesota Mining And Manufacturing Company Patterned array of uniform metal microbeads
US5498545A (en) 1994-07-21 1996-03-12 Vestal; Marvin L. Mass spectrometer system and method for matrix-assisted laser desorption measurements
US6361944B1 (en) 1996-07-29 2002-03-26 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US5900481A (en) 1996-11-06 1999-05-04 Sequenom, Inc. Bead linkers for immobilizing nucleic acids to solid supports
US6327410B1 (en) 1997-03-14 2001-12-04 The Trustees Of Tufts College Target analyte sensors utilizing Microspheres
US5928952A (en) 1997-11-05 1999-07-27 Zymark Corporation Scheduled system and method for processing chemical products
US6413780B1 (en) 1998-10-14 2002-07-02 Abbott Laboratories Structure and method for performing a determination of an item of interest in a sample
ATE444481T1 (de) 1998-11-16 2009-10-15 California Inst Of Techn Gleichzeitige bestimmung von gleichgewichts- und kinetischen eigenschaften
DE19852928C1 (de) 1998-11-17 2000-08-03 Steffen Panzner Strukturen in Form von Hohlkugeln
US20020009394A1 (en) 1999-04-02 2002-01-24 Hubert Koster Automated process line
US8080380B2 (en) 1999-05-21 2011-12-20 Illumina, Inc. Use of microfluidic systems in the detection of target analytes using microsphere arrays
US6969615B2 (en) 1999-07-26 2005-11-29 20/20 Genesystems, Inc. Methods, devices, arrays and kits for detecting and analyzing biomolecules
EP1212599A2 (en) 1999-08-30 2002-06-12 Illumina, Inc. Methods for improving signal detection from an array
US6770441B2 (en) 2000-02-10 2004-08-03 Illumina, Inc. Array compositions and methods of making same
US7892854B2 (en) 2000-06-21 2011-02-22 Bioarray Solutions, Ltd. Multianalyte molecular analysis using application-specific random particle arrays
AU2001296809A1 (en) 2000-10-10 2002-04-22 Biotrove, Inc. Apparatus for assay, synthesis and storage, and methods of manufacture, use, and manipulation thereof
US6482936B1 (en) 2001-04-17 2002-11-19 Pe Corporation (Ny) Isolated human secreted proteins, nucleic acid molecules encoding human secreted proteins, and uses thereof
US6780602B2 (en) 2001-11-01 2004-08-24 Microbiosystems, Limited Partnership Taxonomic identification of pathogenic microorganisms and their toxic proteins
AU2002358343A1 (en) 2002-04-08 2003-12-19 Bioinfra Inc. Method and system for analysis of cancer biomarkers using proteome image mining
JP2005523692A (ja) 2002-04-26 2005-08-11 アボット・ラボラトリーズ 生物学的検定において磁性粒子を処理するための構造体および方法
WO2003101972A1 (en) 2002-05-30 2003-12-11 The Scripps Research Institute Copper-catalysed ligation of azides and acetylenes
US20040153249A1 (en) 2002-08-06 2004-08-05 The Johns Hopkins University System, software and methods for biomarker identification
DE10247896B4 (de) 2002-10-14 2007-01-18 Bruker Daltonik Gmbh Mehrdimensionale Trennung von Biosubstanzgemischen für massenspektrometrische Analysen
US7695738B2 (en) 2003-02-19 2010-04-13 Academia Sinica Carbohydrate encapsulated nanoparticles
US7425700B2 (en) 2003-05-22 2008-09-16 Stults John T Systems and methods for discovery and analysis of markers
US8574590B2 (en) 2003-07-30 2013-11-05 Integral Molecular, Inc. Lipoparticles comprising proteins, methods of making, and using the same
US20040106131A1 (en) 2003-08-18 2004-06-03 Swapan Roy Compositions and methods for proteomic investigations
US7563569B2 (en) 2003-10-28 2009-07-21 Michael Seul Optimization of gene expression analysis using immobilized capture probes
EP1580559B1 (en) 2004-03-23 2013-12-25 Bio-Rad Laboratories, Inc. Methods for reducing the variance between analyte concentrations taken from complex sample mixtures
US9488655B2 (en) 2004-07-14 2016-11-08 The Regents Of The University Of California Biomarkers for detection of early- and late-stage endometrial cancer
CN102759466A (zh) 2004-09-15 2012-10-31 英特基因有限公司 微流体装置
DE102004051785B4 (de) 2004-10-25 2008-04-24 Bruker Daltonik Gmbh Proteinprofile mit Luft-MALDI
TW200640596A (en) 2005-01-14 2006-12-01 Cabot Corp Production of metal nanoparticles
US8288169B2 (en) 2005-01-21 2012-10-16 Argylla Technologies Surface mediated self-assembly of nanoparticles
US9002652B1 (en) 2005-01-27 2015-04-07 Institute For Systems Biology Methods for identifying and using organ-specific proteins in blood
GB0514910D0 (en) 2005-07-20 2005-08-24 Solexa Ltd Method for sequencing a polynucleotide template
WO2007070682A2 (en) 2005-12-15 2007-06-21 Massachusetts Institute Of Technology System for screening particles
JP2009520989A (ja) 2005-12-20 2009-05-28 ザ オハイオ ステイト ユニバーシティ リサーチ ファウンデーション 分析法のためのナノ多孔性基材
US9347945B2 (en) 2005-12-22 2016-05-24 Abbott Molecular Inc. Methods and marker combinations for screening for predisposition to lung cancer
EP3153860A3 (en) 2005-12-22 2017-06-14 Abbott Molecular Inc. Methods and marker combinations for screening for predisposition to lung cancer
EP1982174A4 (en) 2006-01-27 2009-05-06 Univ George Mason EYES LIQUID MARKER
WO2008030631A2 (en) 2006-02-03 2008-03-13 Microchip Biotechnologies, Inc. Microfluidic devices
EP1987159B2 (en) 2006-02-08 2020-08-12 Illumina Cambridge Limited Method for sequencing a polynucleotide template
WO2008073168A2 (en) 2006-08-25 2008-06-19 The Trustees Of Columbia University In The City Of New York Systems and methods for high-throughput radiation biodosimetry
US7815803B2 (en) 2007-06-14 2010-10-19 Roche Diagnostics Operations, Inc. Preparation of samples for LC-MS/MS using magnetic particles
CN101855553B (zh) 2007-06-29 2014-06-11 韩国安国药品株式会社 卵巢癌的预测标记
US8877454B2 (en) 2007-10-05 2014-11-04 National University Corporation Hokkaido University Apparatus for auto-pretreating sugar chain
ES2448426T3 (es) 2007-10-12 2014-03-13 Pronota Nv Uso de aptámeros en proteómica
EP2205662B1 (en) 2007-10-29 2016-07-13 Csir Emulsion-derived particles
US8021891B2 (en) 2007-11-28 2011-09-20 University Of Massachusetts Methods and compositions for protein detection using nanoparticle-fluorescent polymer complexes
US8796184B2 (en) 2008-03-28 2014-08-05 Sentilus, Inc. Detection assay devices and methods of making and using the same
KR101039629B1 (ko) 2008-05-22 2011-06-08 성균관대학교산학협력단 생체물질의 검출방법, 생체물질 검출용 칩의 제조방법 및생물질 검출용 칩
US9333163B2 (en) 2008-10-06 2016-05-10 Massachusetts Institute Of Technology Particles with multiple functionalized surface domains
WO2010078601A1 (en) 2009-01-05 2010-07-08 The Regents Of The University Of California High throughput biomolecule separation and analysis
WO2010083252A2 (en) 2009-01-14 2010-07-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Ratio based biomarkers and methods of use thereof
WO2010097785A1 (en) 2009-02-26 2010-09-02 University College Dublin, National University Of Ireland, Dublin A method for the selective concentration of a specific low abundance biomolecule
WO2010101708A2 (en) * 2009-03-04 2010-09-10 University Of Maine System Board Of Trustees Microfluidic device and related methods
US20120190574A1 (en) 2009-06-19 2012-07-26 The Arizona Board of Regents, A body Corporate of the State of Arizona for and on behalf of Arizona Compound Arrays for Sample Profiling
EP2494364A1 (en) 2009-10-29 2012-09-05 Tethys Bioscience, Inc. Protein and lipid biomarkers providing consistent improvement to the prediction of type 2 diabetes
US9910040B2 (en) 2012-07-09 2018-03-06 Sevident, Inc. Molecular nets comprising capture agents and linking agents
US9005994B2 (en) 2010-01-14 2015-04-14 University Of Central Florida Research Foundation, Inc. Methods for biomolecule and biomolecule complex (BMC) detection and analysis and the use of such for research and medical diagnosis
AU2011215789A1 (en) 2010-02-10 2012-08-30 The Regents Of The University Of California Salivary biomarkers for lung cancer detection
US9149432B2 (en) 2010-03-19 2015-10-06 Massachusetts Institute Of Technology Lipid vesicle compositions and methods of use
US20120171694A1 (en) 2010-07-30 2012-07-05 Vermillion, Inc. Predictive markers and biomarker panels for ovarian cancer
WO2012031205A2 (en) 2010-09-03 2012-03-08 The Brigham And Women's Hospital, Inc. Lipid-polymer hybrid particles
US8759038B2 (en) 2010-09-29 2014-06-24 Illumina Cambridge Limited Compositions and methods for sequencing nucleic acids
US9329176B2 (en) 2010-11-18 2016-05-03 Academia Sinica Glycopeptide-functionalized nanoparticles arrays for capturing and detecting biomolecules
JP6069224B2 (ja) 2011-01-31 2017-02-01 アプライズ バイオ， インコーポレイテッド 細胞において複数のエピトープを同定する方法
GB201103726D0 (en) 2011-03-04 2011-04-20 Immunovia Ab Method, array and use thereof
JP2014526032A (ja) 2011-06-07 2014-10-02 カリス ライフ サイエンシズ ルクセンブルク ホールディングス エス．アー．エール．エル． 癌に対する循環バイオマーカー
US9624524B2 (en) 2011-06-15 2017-04-18 Massachusetts Institute Of Technology In vivo proteomic mapping
US20130058923A1 (en) 2011-08-03 2013-03-07 Qun Huo Biomolecular interactions and interaction products as biomarkers for detection, diagnosis, prognosis and predicting therapeutic responses of human diseases
KR20140067001A (ko) 2011-08-08 2014-06-03 카리스 라이프 사이언스 룩셈부르크 홀딩스, 에스.에이.알.엘. 생물지표 조성물 및 방법
DE202013012824U1 (de) 2012-09-04 2020-03-10 Guardant Health, Inc. Systeme zum Erfassen von seltenen Mutationen und einer Kopienzahlvariation
US10876152B2 (en) 2012-09-04 2020-12-29 Guardant Health, Inc. Systems and methods to detect rare mutations and copy number variation
KR101874501B1 (ko) 2013-03-15 2018-07-05 익스프레션 패톨로지, 인크. 암 요법을 지시하는 srm 검정
WO2014176435A2 (en) 2013-04-25 2014-10-30 Bergo Vladislav B Microarray compositions and methods of their use
WO2015099985A2 (en) 2013-12-23 2015-07-02 The Brigham And Women's Hospital, Inc. Cationic materials and formulations for drug delivery
US9594085B2 (en) 2014-02-03 2017-03-14 Integrated Diagnostics, Inc. Integrated quantification method for protein measurements in clinical proteomics
ES2998535T3 (en) 2014-02-07 2025-02-20 European Molecular Biology Laboratory Proteomic sample preparation using paramagnetic beads
US9446148B2 (en) 2014-10-06 2016-09-20 Mayo Foundation For Medical Education And Research Carrier-antibody compositions and methods of making and using the same
ES2763318T3 (es) 2014-10-06 2020-05-28 Mayo Found Medical Education & Res Composiciones de vehículo-anticuerpo y procedimientos para preparar y usar las mismas
WO2016061201A1 (en) 2014-10-14 2016-04-21 The Brigham And Women's Hospital, Inc. Nanoparticles and methods of use
PL4574996T3 (pl) 2014-12-31 2026-03-02 Guardant Health, Inc. Wykrywanie i leczenie chorób wykazujących heterogeniczność komórek chorobowych oraz systemy i sposoby przekazywania wyników testów
EP3259371B1 (en) * 2015-02-19 2020-09-02 Becton, Dickinson and Company High-throughput single-cell analysis combining proteomic and genomic information
WO2016145416A2 (en) 2015-03-11 2016-09-15 The Broad Institute, Inc. Proteomic analysis with nucleic acid identifiers
US10900975B2 (en) 2015-05-12 2021-01-26 Arizona Board Of Regents On Behalf Of Arizona State University Systems and methods of epitope binning and antibody profiling
US11474102B2 (en) 2015-11-23 2022-10-18 Massachusetts Institute Of Technology Protein corona phase molecular recognition
EP3386551A4 (en) 2015-12-11 2018-10-24 The General Hospital Corporation Dextran nanoparticles for macrophage specific imaging and therapy
TWI760319B (zh) 2015-12-30 2022-04-11 杏國新藥股份有限公司 乳癌治療
WO2017173453A1 (en) 2016-04-01 2017-10-05 The Brigham And Women's Hospital, Inc. Stimuli-responsive nanoparticles for biomedical applications
US20190130994A1 (en) 2016-04-11 2019-05-02 Discerndx, Inc. Mass Spectrometric Data Analysis Workflow
GB201615128D0 (en) 2016-09-06 2016-10-19 Univ Manchester Methods
DK3548652T3 (da) 2016-12-01 2024-07-08 Nautilus Subsidiary Inc Fremgangsmåder til proteinanalyse
WO2018112470A1 (en) 2016-12-16 2018-06-21 The Brigham And Women's Hospital, Inc. Co-delivery of nucleic acids for simultaneous suppression and expression of target genes
US20210072255A1 (en) 2016-12-16 2021-03-11 The Brigham And Women's Hospital, Inc. System and method for protein corona sensor array for early detection of diseases
PT3554681T (pt) 2016-12-16 2022-03-21 Brigham & Womens Hospital Inc Método para matriz de sensores de coroa de proteínas para a deteção precoce de doenças
US11009411B2 (en) 2017-08-14 2021-05-18 Sentons Inc. Increasing sensitivity of a sensor using an encoded signal
CN109593835B (zh) 2017-09-29 2023-12-12 深圳华大基因股份有限公司 用于微量ffpe rna样本评估的方法、试剂盒及应用
EP3701066B1 (en) 2017-10-23 2024-10-16 Nautilus Subsidiary, Inc. Methods and systems for protein identification
WO2019084158A1 (en) 2017-10-26 2019-05-02 Ultima Genomics, Inc. METHODS AND SYSTEMS FOR SEQUENCE CALL
WO2019089846A1 (en) 2017-10-31 2019-05-09 Encodia, Inc. Methods and compositions for polypeptide analysis
US10829815B2 (en) * 2017-11-17 2020-11-10 10X Genomics, Inc. Methods and systems for associating physical and genetic properties of biological particles
WO2019108851A1 (en) 2017-11-30 2019-06-06 10X Genomics, Inc. Systems and methods for nucleic acid preparation and analysis
EP3502708B1 (en) 2017-12-21 2023-09-27 Tecan Trading AG Monitoring a laboratory automation device via a simulation model
IL326759A (en) 2017-12-29 2026-04-01 Nautilus Subsidiary Inc Decoding approaches for protein identification
WO2019209888A1 (en) 2018-04-23 2019-10-31 Seer, Inc. Systems and methods for complex biomolecule sampling and biomarker discovery
CN118272510A (zh) 2018-07-26 2024-07-02 莱森特生物公司 使用单个流动池的多重测序
US11702450B2 (en) 2018-08-30 2023-07-18 Université de Montréal Proteogenomic-based method for identifying tumor-specific antigens
CA3115991A1 (en) 2018-10-12 2020-04-16 Human Longevity, Inc. Multi-omic search engine for integrative analysis of cancer genomic and clinical data
US20220122692A1 (en) 2019-02-11 2022-04-21 Flagship Pioneering Innovations Vi, Llc Machine learning guided polypeptide analysis
CA3131402A1 (en) 2019-03-26 2020-10-01 Xiaoyan Zhao Compositions, methods and systems for protein corona analysis from biofluids and uses thereof
KR20240137114A (ko) 2019-08-05 2024-09-19 시어 인코퍼레이티드 샘플 제조, 데이터 생성, 및 단백질 코로나 분석을 위한 시스템 및 방법
WO2021030460A1 (en) 2019-08-12 2021-02-18 Baylor College Of Medicine Proteogenomic methods for diagnosing cancer
WO2021087407A1 (en) 2019-11-02 2021-05-06 Seer, Inc. Systems for protein corona analysis
EP3901956A1 (en) 2020-04-21 2021-10-27 ETH Zürich Methods of determining correspondences between biological properties of cells
US20230212647A1 (en) 2020-05-29 2023-07-06 Seer, Inc. Systems and methods for rapid identification of proteins
GB202010922D0 (en) 2020-07-15 2020-08-26 Univ London Queen Mary Method
IL299998A (en) 2020-07-20 2023-03-01 Seer Inc Particles and test methods
US20220036968A1 (en) 2020-07-30 2022-02-03 Frontier Medicines Corporation Processing biophysical screening data and identifying and characterizing protein sites for drug discovery
GB2597997A (en) 2020-08-14 2022-02-16 Victoria Yates Emma Method of identifying the presence and/or concentration and/or amount of proteins or proteomes
JP2023540904A (ja) 2020-08-25 2023-09-27 シアー， インコーポレイテッド タンパク質および核酸をアッセイするための組成物および方法
US20220260559A1 (en) 2020-11-04 2022-08-18 Seer, Inc. Biomarkers for diagnosing alzheimer's disease
WO2022108942A1 (en) 2020-11-17 2022-05-27 MOBILion Systems, Inc. Systems and methods for image and/or video processing of mass spectrometry data
US20240125795A1 (en) 2021-02-26 2024-04-18 Seer, Inc. Apparatus for biomolecule assay
US20240219400A1 (en) 2021-04-29 2024-07-04 Seer, Inc. Peptide decorated nanoparticles for enrichment of specific protein subsets
EP4370916A4 (en) 2021-07-13 2025-05-21 Seer, Inc. Systems and methods for processing mass spectrometry datasets
US20230160882A1 (en) 2021-08-24 2023-05-25 Seer, Inc. Compositions and methods for low-volume biomolecule assays
EP4460829A4 (en) 2022-01-07 2026-01-14 Seer Inc Peptide-focused analyses
EP4466538A4 (en) 2022-01-20 2026-01-14 Seer Inc PARTICLES AND ASSAY METHODS
US20230253113A1 (en) 2022-02-04 2023-08-10 Seer, Inc. Systems and methods for creating biomolecule embeddings
US20250157570A1 (en) 2022-02-15 2025-05-15 Seer, Inc. Systems and methods for analyzing omics data
US12437980B2 (en) 2022-05-20 2025-10-07 Sapient Bioanalytics, Llc Mass spectrometry retrieving of stray samples
GB2639321A (en) 2022-08-18 2025-09-24 Seer Inc Methods for using a machine learning algorithm for omic analysis

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020096631A2 (en) * 2018-11-07 2020-05-14 Seer, Inc. Compositions, methods and systems for protein corona analysis and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PROTEOMICS, vol. 14, JPN6025038380, 2014, pages 2742 - 2749, ISSN: 0005689531 *

Also Published As

Publication number Publication date
AU2021333661A1 (en) 2023-03-23
CN116529393A (zh) 2023-08-01
DE112021004478T5 (de) 2023-09-14
US12276668B2 (en) 2025-04-15
US20230408503A1 (en) 2023-12-21
WO2022046804A3 (en) 2022-04-07
IL300826A (en) 2023-04-01
CA3190719A1 (en) 2022-03-03
EP4204580A4 (en) 2025-03-19
CN116529393A8 (zh) 2023-10-27
WO2022046804A2 (en) 2022-03-03
EP4204580A2 (en) 2023-07-05
KR20230079044A (ko) 2023-06-05
US20250244336A1 (en) 2025-07-31

Similar Documents

Publication Publication Date Title
US12276668B2 (en) Compositions and methods for assaying proteins and nucleic acids
JP7803989B2 (ja) サンプル調製、データ生成、タンパク質コロナ分析のためのシステムおよび方法
US20230160882A1 (en) Compositions and methods for low-volume biomolecule assays
JP2025522362A (ja) マルチオミクス評価
US20240125795A1 (en) Apparatus for biomolecule assay
US20230212647A1 (en) Systems and methods for rapid identification of proteins
Cayer et al. Mission critical: the need for proteomics in the era of next-generation sequencing and precision medicine
US20250157570A1 (en) Systems and methods for analyzing omics data
JP2024534992A (ja) 生体分子の増強された検出および定量
Suravajhala et al. Combining aptamers and in silico interaction studies to decipher the function of hypothetical proteins
HK40124213A (zh) 多组学评估
WO2026107397A1 (en) Characterization of the epigenetic landscape in complex fluids
CN117202991A (zh) 用于生物分子测定的装置
Donovan et al. Peptide-centric analyses of human plasma enable increased resolution of biological insights into non-small cell

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240826

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240826

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250820

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250917

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251216

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260216

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260317